The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development ...

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd ...

US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...

The second half of Alan Jackson’s farewell tour resumes next week. The country music legend will perform on Saturday, Jan. 18 ...

A woman in Georgia has filed a police report after an online scammer claiming to be Alan Jackson swindled her out of nearly ...

(Alliance News) - RTW Biotech Opportunities Ltd said on Friday said it is participating in a EUR65 million Series A financing round for Alesta Therapeutics BV, a Leiden, Netherlands-based ...

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and ...

Actio Biosciences, a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop ...

When Judith Barrington reflects on her latest book, “ Virginia’s Apple: Collected Memoirs ,” she thinks of it as daring, ...

Alesta Therapeutics, a biotechnology company focused on developing transformative small molecule therapies for rare diseases, today announced the closing of an oversubscribed ?65 million Series ...

NMD670 is an oral therapy designed to treat Charcot-Marie-Tooth disease. Credit: SkazovD / Shutterstock. The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD ...